On the morning of October 19, YRPG and Crown Bioscience (Taicang) Inc. held a signing ceremony of R & D and cooperation in Petrel Hotel. Dr. Shi Hepeng, Vice President of Beijing Haiyan Pharmaceutical Co., Ltd. and Dr. Shi Quan from Crown Bioscience (Taicang) Inc. signed the agreement. Song Jianzhong, Chairman of Taicang Municipality of Chinese People's Political Consultative Conference (CPPCC), Lu Dingfeng, Sectary-general of the government, and Xu Jingren, Chairman of YRPG attended the ceremony and witnessed the signing of cooperation.
Crown Bioscience, headquartered in Silicon of USA, is a famous biopharmaceutical company in the world. It is a service provider of a professional CRO. Crown Bioscience has a group of experts studying life science and technical backbone with oversea study and work experience. Besides, it is also domestic high-quality drug development outsourcing service provider and preferred partner of new drug development in many transnational pharmaceutical enterprises. According to the agreement, Crown Bioscience will develop the anti-cancer drug YB-001/IDD001 with YRPG. Through the cooperation, Crown Bioscience and YRPG can make full use of their complementary advantages and work together to develop new drugs for China's cancer market.
YRPG mainly aims to develop innovative drugs with independent intellectual property rights in the future. The cooperation is meaningful. YRPG will try to adopt new development mode and rely on a team with international new drug development experience. In this way, YRPG hopes to accelerate its development, improve its innovative ability, and provide safer and more abundant and effective drugs, and healthy service for Chinese patients.